Cargando…
The Antibody Society’s antibody validation webinar series
In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commerc...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531563/ https://www.ncbi.nlm.nih.gov/pubmed/32748696 http://dx.doi.org/10.1080/19420862.2020.1794421 |
_version_ | 1783589781534408704 |
---|---|
author | Voskuil, Jan L.A. Bandrowski, Anita Begley, C. Glenn Bradbury, Andrew R.M. Chalmers, Andrew D. Gomes, Aldrin V. Hardcastle, Travis Lund-Johansen, Fridtjof Plückthun, Andreas Roncador, Giovanna Solache, Alejandra Taussig, Michael J. Trimmer, James S. Williams, Cecilia Goodman, Simon L. |
author_facet | Voskuil, Jan L.A. Bandrowski, Anita Begley, C. Glenn Bradbury, Andrew R.M. Chalmers, Andrew D. Gomes, Aldrin V. Hardcastle, Travis Lund-Johansen, Fridtjof Plückthun, Andreas Roncador, Giovanna Solache, Alejandra Taussig, Michael J. Trimmer, James S. Williams, Cecilia Goodman, Simon L. |
author_sort | Voskuil, Jan L.A. |
collection | PubMed |
description | In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered. |
format | Online Article Text |
id | pubmed-7531563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-75315632020-10-13 The Antibody Society’s antibody validation webinar series Voskuil, Jan L.A. Bandrowski, Anita Begley, C. Glenn Bradbury, Andrew R.M. Chalmers, Andrew D. Gomes, Aldrin V. Hardcastle, Travis Lund-Johansen, Fridtjof Plückthun, Andreas Roncador, Giovanna Solache, Alejandra Taussig, Michael J. Trimmer, James S. Williams, Cecilia Goodman, Simon L. MAbs Perspective In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered. Taylor & Francis 2020-08-04 /pmc/articles/PMC7531563/ /pubmed/32748696 http://dx.doi.org/10.1080/19420862.2020.1794421 Text en © 2020 The Authors. Published with license by Taylor & Francis, LLC https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Perspective Voskuil, Jan L.A. Bandrowski, Anita Begley, C. Glenn Bradbury, Andrew R.M. Chalmers, Andrew D. Gomes, Aldrin V. Hardcastle, Travis Lund-Johansen, Fridtjof Plückthun, Andreas Roncador, Giovanna Solache, Alejandra Taussig, Michael J. Trimmer, James S. Williams, Cecilia Goodman, Simon L. The Antibody Society’s antibody validation webinar series |
title | The Antibody Society’s antibody validation webinar series |
title_full | The Antibody Society’s antibody validation webinar series |
title_fullStr | The Antibody Society’s antibody validation webinar series |
title_full_unstemmed | The Antibody Society’s antibody validation webinar series |
title_short | The Antibody Society’s antibody validation webinar series |
title_sort | antibody society’s antibody validation webinar series |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531563/ https://www.ncbi.nlm.nih.gov/pubmed/32748696 http://dx.doi.org/10.1080/19420862.2020.1794421 |
work_keys_str_mv | AT voskuiljanla theantibodysocietysantibodyvalidationwebinarseries AT bandrowskianita theantibodysocietysantibodyvalidationwebinarseries AT begleycglenn theantibodysocietysantibodyvalidationwebinarseries AT bradburyandrewrm theantibodysocietysantibodyvalidationwebinarseries AT chalmersandrewd theantibodysocietysantibodyvalidationwebinarseries AT gomesaldrinv theantibodysocietysantibodyvalidationwebinarseries AT hardcastletravis theantibodysocietysantibodyvalidationwebinarseries AT lundjohansenfridtjof theantibodysocietysantibodyvalidationwebinarseries AT pluckthunandreas theantibodysocietysantibodyvalidationwebinarseries AT roncadorgiovanna theantibodysocietysantibodyvalidationwebinarseries AT solachealejandra theantibodysocietysantibodyvalidationwebinarseries AT taussigmichaelj theantibodysocietysantibodyvalidationwebinarseries AT trimmerjamess theantibodysocietysantibodyvalidationwebinarseries AT williamscecilia theantibodysocietysantibodyvalidationwebinarseries AT goodmansimonl theantibodysocietysantibodyvalidationwebinarseries AT voskuiljanla antibodysocietysantibodyvalidationwebinarseries AT bandrowskianita antibodysocietysantibodyvalidationwebinarseries AT begleycglenn antibodysocietysantibodyvalidationwebinarseries AT bradburyandrewrm antibodysocietysantibodyvalidationwebinarseries AT chalmersandrewd antibodysocietysantibodyvalidationwebinarseries AT gomesaldrinv antibodysocietysantibodyvalidationwebinarseries AT hardcastletravis antibodysocietysantibodyvalidationwebinarseries AT lundjohansenfridtjof antibodysocietysantibodyvalidationwebinarseries AT pluckthunandreas antibodysocietysantibodyvalidationwebinarseries AT roncadorgiovanna antibodysocietysantibodyvalidationwebinarseries AT solachealejandra antibodysocietysantibodyvalidationwebinarseries AT taussigmichaelj antibodysocietysantibodyvalidationwebinarseries AT trimmerjamess antibodysocietysantibodyvalidationwebinarseries AT williamscecilia antibodysocietysantibodyvalidationwebinarseries AT goodmansimonl antibodysocietysantibodyvalidationwebinarseries |